Purpose: To report a case of a full-thickness macular hole (MH) that developed after cryotherapy and intravitreal bevacizumab injection (IVB) to treat a retinal vasoproliferative tumor (VPT).
Methods: Case report of a man with a retinal VPT.
Results: A 64-year-old Japanese man complained of blurred vision in his right eye. At the initial examination, his best-corrected visual acuity (BCVA) was 20/25 in the right eye and 20/20 in the left eye. Ophthalmoscopy showed a VPT in the lower peripheral retina of the right eye. An exudative retinal detachment and hard exudates were seen around the tumor. Cryotherapy and intravitreal injections of bevacizumab (IVB) were performed. Although the exudative changes were reduced, a MH developed two months after the initial IVB treatment. He underwent 25-gauge pars plana vitrectomy, and the MH was closed. His postoperative BCVA was 20/32 and the VPT was inactive. The reduced BCVA was due to damage of the outer retinal layers.
Conclusion: Our findings indicate that cryotherapy and IVB are effective treatments for VPT although the possibility of developing a MH should be considered.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501591 | PMC |
| http://dx.doi.org/10.2147/IMCRJ.S266986 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aim: Evaluation of screening and treatment of retinopathy of prematurity (ROP) at the Department of Pediatric Ophthalmology.
Material And Methods: Retrospective evaluation of the medical records of premature babies, born in the period 2012-2022 and treated at the Neonatology Department and the Neonatology ICU at the University Hospital Brno. On average 150 children annually are put forward for screening of ROP.
Prospects of anti-GD2 immunotherapy for retinoblastoma.
Front Immunol
December 2024
Affiliated Hospital of Shandong Second Medical University,School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
Article Synopsis
- - Retinoblastoma is the most common eye tumor in young children, and existing treatments like chemotherapy and surgery can have serious side effects, including blindness and toxic reactions.
- - Immunotherapy, especially targeting the GD2 sphingolipid found on retinoblastoma cells, shows promise due to its lower toxicity and potential to improve patient quality of life.
- - Anti-GD2 therapies, such as the monoclonal antibody Dinutuximab, CAR-T therapy, GD2 vaccines, and nanoparticles are emerging as effective treatments, but there are still challenges to overcome in their application.
Clinical Presentation and Treatment Outcomes of Adult-Onset Coats Disease.
J Vitreoretin Dis
September 2024
Department of eyeSmart EMR & AEye, LV Prasad Eye Institute, Hyderabad, Telangana, India.
To study the clinical profile, treatment, and outcomes of patients 35 years or older diagnosed with Coats disease. A cross-sectional observational hospital-based study was performed. The study included 74 eyes diagnosed with adult-onset Coats disease.
View Article and Find Full Text PDFHIGH-DOSE INTRAVITREAL TOPOTECAN FOR RECURRENT RETINOBLASTOMA, SUBRETINAL SEEDS, AND VITREOUS SEEDS.
Retina
January 2025
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania.
Article Synopsis
- The study assessed the effectiveness and safety of high-dose intravitreal topotecan (IvitTopo) in treating patients with recurrent retinoblastoma, with outcomes focused on tumor control, eye preservation, and any potential treatment side effects.
- Thirteen patients, primarily infants, received high-dose IvitTopo after experiencing tumor recurrence, resulting in a significant regression of tumors in 92% of cases and complete eye salvage in all patients.
- The results suggest that high-dose IvitTopo is not only effective but also safe for managing recurrent retinoblastoma, and it may work well alone or alongside other treatments.
How Much Time Do Focal Treatments for Retinoblastoma Add to Anesthetic Exposure?
Ocul Oncol Pathol
September 2024
Department of Surgery, Ophthalmic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Introduction: Children with retinoblastoma have anesthesia for exams and treatment, but there is little information about how long treatment interventions (laser, cryotherapy, and intravitreal injections) add to routine exams under anesthesia (EUA). This information would be useful for planning operating room schedules, staff schedules, family expectations, and billing.
Methods: A retrospective, single-center, Institutional Review Board (IRB) approved review of anesthesia duration for retinoblastoma children undergoing EUA with laser, cryotherapy, or intravitreal injections performed at MSK between January 2019 and November 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!